Evidence map›Paper›PMID 37343217›Full record

ArticleThe international journal of neuropsychopharmacology2023

Activation of the Mu-Delta Opioid Receptor Heteromers Blocks Morphine Rewarding Effects.

Ariadna Requana Aradas, Youssra Djaboub, Isabelle McCort-Tranchepain, Zuzana Hajasova, Loïc Clémenceau, Corinne Canestrelli, Anika Mann, Stefan Schulz, Angélique Delaval, Francine Acher and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Ariadna Requana AradasUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Youssra DjaboubUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Isabelle McCort-TranchepainUniversité Paris Cité, CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Paris, France.ORCID 0000-0001-7447-8806
Zuzana HajasovaUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Loïc ClémenceauUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Corinne CanestrelliUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Anika MannFriedrich Schiller University Jena, Jena University Hospital, Institute of Pharmacology and Toxicology, Jena, Germany.
Stefan SchulzFriedrich Schiller University Jena, Jena University Hospital, Institute of Pharmacology and Toxicology, Jena, Germany.
Angélique DelavalUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Francine AcherUniversité Paris Cité, CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Paris, France.
Dominique MassotteUniversité de Strasbourg, CNRS, Institut des Neurosciences Cellulaires et Intégratives, Strasbourg, France.
Florence NobleUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Nicolas MarieUniversité Paris Cité, CNRS, Inserm, Pharmacologie et thérapies des addictions, Paris, France.
Centre National de la Recherche Scientifique · FRJena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence has accumulated demonstrating the existence of opioid receptor heteromers, and recent data suggest that targeting these heteromers could reduce opioid side effects while retaining therapeutic effects. Indeed, CYM51010 characterized as a MOR (mu opioid receptor)/DOR (delta opioid receptor) heteromer-preferring agonist promoted antinociception comparable with morphine but with less tolerance. In the perspective of developing these new classes of pharmacological agents, data on their putative side effects are mandatory.

methodsTherefore, in this study, we investigated the effects of CYM51010 in different models related to drug addiction in mice, including behavioral sensitization, conditioned place preference and withdrawal.

resultsWe found that, like morphine, CYM51010 promoted acute locomotor activity as well as psychomotor sensitization and rewarding effect. However, it induced less physical dependence than morphine. We also investigated the ability of CYM51010 to modulate some morphine-induced behavior. Whereas CYM51010 was unable to block morphine-induced physical dependence, it blocked reinstatement of an extinguished morphine induced-conditioned place preference.

conclusionsAltogether, our results reveal that targeting MOR-DOR heteromers could represent a promising strategy to block morphine reward.

Indexed as

MorphineReceptors, Opioid, deltaAnalgesics, OpioidAnimalsMiceReceptors, Opioid, muRewardAnalgesics, OpioidMorphineReceptors, Opioid, deltaReceptors, Opioid, mubehavioral sensitizationCYM51010MOR-DOR heteromersmorphinerewardwithdrawal

Identifiers

PMID37343217
PMCPMC10388387
OpenAlexW4381598063

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.